Statistics from Altmetric.com
For non-ambulatory children with severe physical and cognitive disabilities (SPCD), being lifted and transported become more challenging with increasing size. Reduction in length and overall size for select children with SPCD can be accomplished by growth attenuation therapy (GAT), which reduces linear growth by administering hormones (eg, oestrogen) that accelerate epiphyseal closure. There are no reliable data describing attitudes and practices of paediatric endocrinologists regarding GAT for children with SPCD.
In collaboration with the Pediatric Endocrine Society (PES), an anonymous questionnaire about GAT was emailed to PES physician members (n=1100, 92% from the USA). Responses were stripped of identifiable information. Consent was implied by responding. The study received institutional review board exemption status at the University of Wisconsin–Madison.
Two hundred and eighty-four PES members responded …
Contributors AJP: Conceptualised and designed the study and questionnaire instrument, carried out the initial analyses, drafted the initial manuscript and approved the final manuscript as submitted. NF and DBA: Contributed to the design and analyses, critically reviewed and revised the manuscript and approved the final manuscript as submitted.
Competing interests None declared.
Ethics approval University of Wisconsin Institutional Review Board.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.